Particle News: Latest Valneva SE news

FDA Suspends Valneva’s Ixchiq Chikungunya Vaccine Over Safety Reports

The move follows fresh post‑marketing data that regulators say show the live vaccine can cause chikungunya‑like illness in some recipients.

FDA Suspends Valneva’s Ixchiq Chikungunya Vaccine in the U.S. After New Serious Adverse Reports

Paris Stocks Slip as Tech Selloff Checks Rally Before Jackson Hole

Equity Markets Climb on Steady US Inflation and 90-Day US-China Tariff Truce Extension

FDA Lifts Pause on Valneva’s Chikungunya Vaccine for Seniors

U.S. Emergency Room Visits for Tick Bites Reach Five-Year High as Vaccine and Anti-Tick Trials Advance

FDA and CDC Pause Chikungunya Vaccine for Older Adults Over Safety Concerns

Federal Vaccine Panel Expands RSV, Meningitis, and Chikungunya Recommendations